Targeted HFpEF therapy based on matchmaking of human and animal models

Research output: Contribution to journalReview articlepeer-review

11 Citations (Web of Science)

Abstract

Targeted HFpEF therapy based on matchmaking of human and animal models. Am J Physiol Heart Circ Physiol 315: H1670-H1683, 2018. First published September 21, 2018; doi:10.1152/ajpheart.00024.2018. The diversity in clinical phenotypes and poor understanding of the underlying pathophysiology of heart failure with preserved ejection fraction (HFpEF) is the main reason why no effective treatments have been found yet. Targeted, instead of one size fits all, treatment seems the only promising approach for treating 1114pE14. To be able to design a targeted, phenotype-specific HFpEF treatment, the matrix relating clinical phenotypes and underlying pathophysiological mechanisms has to be clarified. This review discusses the opportunities for additional evaluation of the underlying pathophysiological processes, e.g., to evaluate biological phenotypes on top of clinical routine, to guide us toward a phenotype specific HFpEF treatment. Moreover, a translational approach with matchmaking of animal models to biological HFpEF phenotypes will be a valuable step to test the effectiveness of novel, targeted interventions in IIFpEF.

Original languageEnglish
Pages (from-to)H1670-H1683
Number of pages14
JournalAmerican Journal of Physiology-heart and Circulatory Physiology
Volume315
Issue number6
DOIs
Publication statusPublished - Dec 2018

Keywords

  • heart failure with preserved ejection fraction
  • inflammation
  • personalized medicine
  • translational research
  • trial design
  • PRESERVED EJECTION FRACTION
  • CHRONIC HEART-FAILURE
  • LEFT-VENTRICULAR FUNCTION
  • C-REACTIVE PROTEIN
  • DIASTOLIC DYSFUNCTION
  • CARDIAC FIBROSIS
  • ANGIOTENSIN-II
  • ENDOTHELIAL DYSFUNCTION
  • MYOCARDIAL DYSFUNCTION
  • CHRONIC INHIBITION

Cite this